Corvus Pharmaceuticals
CRVS
164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
185% more capital invested
Capital invested by funds: $359M → $1.02B (+$665M)
172% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 25
158% more call options, than puts
Call options by funds: $21M | Put options by funds: $8.14M
83% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 30
32% more funds holding
Funds holding: 124 → 164 (+40)
20.94% more ownership
Funds ownership: 62.51% → 83.45% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$46M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$39.8M |
| 3 |
CC
Commodore Capital
New York
|
+$36M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$32M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.1M |
| 2 |
Morgan Stanley
New York
|
-$17.1M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.1M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$6.03M |
| 5 |
Jane Street
New York
|
-$5.33M |
CRVS Hedge Fund Activity: Q1 2026 in Review
164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.
- 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
- Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
- 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
- The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.
Based on aggregated 13F filings for Q1 2026.